The use of artesunate&mrfloquine in Pregnancy.

Abstract

A retrospective study of the outcome of Artesunate & Mefloquine was carried out on 16 complicated malaria pregnancies in Trat hospital since April 1998-May 2003. These infected cases were treated with the combination of Artesunate & Mefloquine and treated other medical complications. The maternal mortality rate were 0 percent. The fetal outcome were abortion 7.6 percent, premature deliveries 7.6 percent, term delivery 84.6 percent. It was noted that the undesirable outcome of the fetus canût be concluded because of many other risk factors. The clinical study has demonstrated the general safety and efficacy of Artesunate& Mefloquine in pregnant mother with their desirable clinical properties such as rapidly of action and maintained activity even in patients carrying multidrug resistant parasites. So their use in pregnancy has been left for decision by the physician making a risk-benefit assessment in the individual patient.